Colorectal Cancer Drug Futures

Date: October 22, 2010
Price:
US$ 2,615.00
Publisher: Espicom Business Intelligence
Report type: Strategic Report
Delivery: E-mail Delivery (PDF)
ID: CB79BD7FA04EN
Leaflet:

Download PDF Leaflet

Colorectal Cancer Drug Futures
AN EXCEPTIONALLY COST EFFECTIVE SERVICE INCLUDING FORMATS TO MEET EVERY INFORMATION NEED

Espicom's Colorectal Cancer Drug Futures includes formats to meet differing information requirement of customers. For constant vigilance and up-to-date coverage of lung cancer drug development users can access the 24/7 daily updated web service. For strategic periodic reviews we also provide quarterly-updated reports of all drugs in a convenient pdf document. All for one cost-effective annual price of £1,495/US$2,615/€1,865

24/7 web access
Quarterly updated pdf reports
Single cost-effective price
All updates including any new drugs added during your license period
Related news
Espicom’s research methodology for forecasting and including an explanation of the competitor ratio analysis scoring system.

Early-stage colorectal cancer (CRC) is generally treated with surgery and radiation....
....with a high percentage of patients going on to survive disease free. Unfortunately, only around 40% of CRCs are found at this early stage, and, as a result, there remains considerable unmet clinical need within the CRC market.

For those patients who experience recurrence following surgery there is a clear need for effective therapies earlier in the course of the disease. In addition, with around 76% of patients (Stages II-IV) eligible for chemotherapy, new formulations which improve patients' quality of life and increase survival are sorely needed.

In 2008, the CRC drug market (US, EU and Japan) for major branded therapies was valued at just over US$8 billion. Whilst chemotherapy is the mainstay of CRC treatment the use of targeted therapies are gaining acceptance in the treatment of advanced disease. This trend is expected to continue as new combinations are evaluated and therapies are increasingly used in the adjuvant setting to address the unmet clinical needs within the market. Indeed, by 2015 targeted therapies will account for 77% of the CRC market.

Which products and companies will benefit from this trend?

NOW YOU CAN STAY IN TOUCH WITH THE DEVELOPMENTS WHICH MATTER

This all new web service from Espicom, Colorectal Cancer Drug Futures, assesses the future prospects for market success for individual drugs. Based on independent research and proprietary analysis, each product assessed brings the prospects for a product into clear focus. Best of all, each drug is regularly reviewed ensuring that latest developments are incorporated for you to see.

WITH EACH KEY DRUG ANALYSED IN THIS SERVICE YOU CAN...
  • Track the drug’s progress and stay abreast of developments
  • Understand the drug’s novelty and mode of action
  • Evaluate the strength of the company developing/producing the drug
  • Review opportunities and challenges with Espicom’s unique 5-point competitive assessment
  • Know the launch timeframe for new products or indications
  • Be aware of promising mid-stage development candidates
  • Estimate future revenues with original 5-year forecasts for launched and leading pipeline candidates
  • Review significant clinical trial results
STRUCTURED ANALYSIS OF KEY DRIVERS AND DAMPENERS OF SUCCESS

For each product analysed there is an extensive and standardised review of the factors which can affect its clinical and commercial performance. Those factors include…
  • Novelty/rationale for mechanism of action
  • Current status
  • Proof of concept/clinical data
  • Development risks
  • Company expertise
  • Competition within the market-place
  • Sales forecast (for key late-stage and launched products)
  • Competitor ratio analysis score
  • Clinical trial results
50 CRC ACTIVE DRUGS INCLUDE:
Because this service is continually updated, products will be added, deleted or enhanced in response to ongoing developments throughout the course of your licence. From time-to-time drug profiles may be removed from the service for essential updating.

Approved
  • Bevacizumab
  • Capecitabine
  • Cetuximab
  • Doxifluridine
  • Irinotecan
  • Oxaliplatin
  • Panitumumab
Phase I/II
  • ARQ 197
  • EMD525797
Phase III
  • Aflibercept
  • Brivanib
  • Cediranib
  • HA-irinotecan
  • OncoVAX
  • Perifosine
  • Regorafenib
  • Talaporfin sodium
Phase I
  • 184072
  • Dulanermin
  • IMO-2055
  • Interleukin-21
  • Pazopanib
  • Tivozanib
Phase II/III
  • Canfosfamide
Discontinued
  • ABT-751
  • GDC-0449
  • PD-325901
  • Trastuzumab
Phase II
  • Adecatumumab
  • Angiocept
  • Arenegyr
  • AZD6244
  • BIBF 1120
  • Cixutumumab
  • Conatumumab
  • CPX-1
  • CS-7017
  • Davanat
  • Enzastaurin
  • Figitumumab
  • GDC-0449
  • Gimatecan
  • Linifanib
  • Mapatumumab
  • Necitumumab
  • Pemetrexed disodium
  • Picoplatin
  • Ramucirumab
  • RG 7204
  • SAR109659
  • Sorafenib
  • Sunitinib
  • TAS-102
  • Telatinib
  • Tigatuzumab
CLEAR, CONCISE, AND ORIGINAL ANALYSIS GIVES YOU KEY PRODUCT INSIGHTS

Espicom's Cancer Drug Futures incorporate the latest analysis from our in-house team of life scientists and statisticians across a range of cancer areas. Their research builds upon Espicom's established knowledge base of up-to-date intelligence on thousands of pharmaceutical manufacturers and research companies, backed up by a fifteen years’ of archive material.

Taking all aspects of the market into account, from clinical trials, deals and alliances to company financial performance and drug sales, the analysis and forecasting that contributes to Espicom's Cancer Drug Futures is standardised across each individual launched product or drug candidate and is founded upon a diligent and thorough research process.

With Espicom’s Cancer Drug Futures you can easily evaluate the prospects of the drugs of interest to you and discover its progress in each indication. Each report provides individual and highly-detailed analysis of the drug, looking at the key factors affecting its future performance in the marketplace.

BUILD YOUR OWN DRUG FUTURES LIBRARY WITH 4D RESEARCH!

4D Research is Espicom’s tailored information service. Using 4D Research, customers can build their own Futures library of individual drugs of interest. Indeed, the service can include any of Espicom’s leading information services. Attractive discounts are available to buyers of multiple Futures and our cost-effective distribution license means these key data can be shared with colleagues.

For further information on the products covered, discounts, distribution or a demonstration, please click on the link for Mark Hamson.

CANCER SECTORS COVERED IN THE DRUG FUTURE SERVICE
  • Breast
  • Lung
  • Colorectal
  • Renal Cell Carcinoma
  • Prostate
  • Blood (coming soon)
OVERVIEW

PHASE I


184072
Current Status

DULANERMIN

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

IMO-2055

Mode of Action
Current Status
Proof of Concept/Clinical Data
Company Expertise
Clinical Trial Results

INTERLEUKIN-21

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

PAZOPANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Competitor Ratio Analysis
Forecast

TIVOZANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

PHASE I/II

ARQ 197


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

EMD 525797

Mode of Action
Current Status

PHASE II

ADECATUMUMAB


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Clinical Trial Results

ANGIOCEPT

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

ARENEGYR

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

AZD6244

Mode of Action
Current Status
Clinical Trial Results
BIBF 1120
Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

CIXUTUMUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

CONATUMUMAB

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis

CPX-1

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

CS-7017

Mode of Action
Current Status

DAVANAT

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

ENZASTAURIN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

FIGITUMUMAB

Mode of Action
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

GDC-0449

Mode of Action
Current Status
Proof of Concet/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

GIMATECAN

Mode of Acion
Proof of Concept/Clinical Data

LINIFANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

MAPATUMUMAB

Mode of Actin
Current Status
Proof of Concept
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

NECITUMUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

PEMETREXED DISODIUM

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results
Metastatic Breast Cancer

PICOPLATIN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Competitor Ratio Analysis

RAMUCIRUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

RG7204

Mode of Action
Current Status
Proof of Concept
Clinical Trial Results

SAR109659

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

SORAFENIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Competitor Ratio Analysis
Forecast
Clinical Trial Results

SUNITINIB MALATE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results

TAS-102

Mode of Action
Current Status

TELATINIB

Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

TIGATUZUMAB

Mode of Action
Current Status

PHASE II/III

CANFOSFAMIDE


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

PHASE III

AFLIBERCEPT


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

BRIVANIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

ERLOTINIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Data Exclusivity
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results

HA-IRINOTECAN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis

ONCOVAX

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

PERIFOSINE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development/Commercialisation Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast

REGORAFENIB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Clinical Trial Results

TALAPORFIN SODIUM

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

LAUNCHED PRODUCTS

BEVACIZUMAB


Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

CAPECITABINE

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Competitor Ratio Analysis
Forecast
Clinical Trial Results

CETUXIMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Generic Competition
Competitor Ratio Analysis
Forecast
Clinical Trial Results

DOXIFLURIDINE

Mode of Action
Current Status

IRINOTECAN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast

OXALIPLATIN

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Generic Competition
Competitor Ratio Analysis
Forecast

PANITUMUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

TEGAFUR+GIMERACIL+OTERACIL

Mode of Action
Current Status
Company Expertise

TEGAFUR+URACIL

Current Status
Company Expertise
Clinical Trial Results

DEVELOPMENT DISCONTINUED

ABT-751


Mode of Action
Current Status

CEDIRANIB

Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition Within the Market-place
Competitor Ratio Analysis
Forecast
Clinical Trial Results

PD-325901

Mode of Action
Current Status
Proof of Concept/Clinical Data

TRASTUZUMAB

Mode of Action
Current Status
Proof of Concept/Clinical Data
Development Risks
Company Expertise
Competition within the Market-place
Patent Expiry
Competitor Ratio Analysis
Forecast
Clinical Trial Results

METHODOLOGY
Skip to top


Breast Cancer Drug Futures US$ 2,615.00 Oct, 2010
Lung Cancer Drug Futures US$ 2,615.00 Oct, 2010
Prostate Cancer Drug Futures US$ 2,615.00 Oct, 2010

Ask Your Question

Colorectal Cancer Drug Futures
Company name*:
Contact person*:
Phone/fax*:
Email*:
Request invoice
Your enquiry:
Please click on a Check Box below to confirm you are not a robot: